Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Explore why price weighting influences benchmark performance and how to account for it in analysis and comparisons.
26,632 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Nvidia CEO Jensen Huang reiterates a generous pay policy as AI-driven profits soar, highlighting how wealth from tech...
Apollo Global Management posted strong 2025 revenue and raised its dividend, but the stock has fallen as private cred...
Analysts weigh whether Credo can reach $350 by 2028 as AI infrastructure spending stays strong and the company accele...
AppLovin stock declines after fresh short-seller concerns about competition surface, even as Q4 numbers show strong c...
As market volatility persists in 2026, a tax-advantaged Roth approach could dramatically lift after-tax income from a...
A new ETF focused on CTAs began trading this week, giving U.S. investors direct exposure to trend-following across mu...
Palantir (PLTR) sits near $152 after a blowout Q1 2026. Investors weigh whether to buy, hold, or sell Palantir stock ...
McDonald’s posted better-than-expected first-quarter sales, yet higher gas prices and consumer anxiety threaten momen...
A niche shipping ETF has delivered extraordinary gains in 2026, turning a $100,000 investment into several million as...
As 2026 unfolds, a mix of rate shifts, debt pressures, and geopolitical strains create a tricky path for investors. T...
The Tortoise AI Infrastructure ETF (TCAI) is drawing attention as data-center power, cooling, and fiber networks surg...